Press Releases

Biosimilars Market Size is Forecasted to Reach US$ 66.2 Billion by 2030

Share This Article

According to Precedence Research, the global biosimilars market size is forecasted to reach US$ 66.2 billion by 2030 from US$ 13.5 billion in 2021, by growing at a lucrative CAGR of 17.5% between 2021 and 2030.

The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2021 to 2030. The report offers exclusive insights to help companies make informed decisions to sustain growth through the assessment period.

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1359

The rising prevalence of diseases and the effective treatment of these chronic diseases at affordable costs are the two major drivers of the global biosimilars market. The biosimilar drugs are very efficient at targeting specific infected cells without damaging the normal cells, which is significantly boosting the adoption of the biosimilar drugs among the global population. The rising government initiatives to drive the adoption of various biosimilar drugs by incorporating favorable changes to the regulations is a positive sign for the manufacturers of the biosimilar drugs.

For instance, Europe approved more than 60 biosimilar brands. Europe is a mature market for the biosimilar drugs. The rising adoption and popularity of the biosimilars in the North America and Asia Pacific is estimated to provide lucrative growth opportunities for the market players to expand in the upcoming future. Further, the rising investments by the market players in the research and development activities are expected to provide new growth avenues in the forthcoming years.

Europe was the dominating market that accounted for over 50% of the market share in 2020. EMA played an important role in augmenting the adoption of the biosimilar drugs in the region. Moreover, the increased disposable income, higher adoption rate of advanced technologies, and increased awareness regarding the biosimilars among the population has spurred the growth of the market in Europe. Further, the presence of numerous players in the region and various developmental strategies adopted by them played a crucial role in the market development.

North America region is estimated to be the most opportunistic market during the forecast period. North America is characterized by the increased demand for the advanced and innovative healthcare products, increased consumer expenditure on healthcare, and active participation of the regulatory authorities to overlook the matters related to the preclinical trials and product launches in the market. FDA in US has recently approved around 20 biosimilar products. The rising popularity of the biosimilar drugs among the patients in the US is expected to propel the demand for the biosimilars in North America.

The rising burden of various chronic diseases such as cardiovascular diseases, diabetes, cancer, and kidney failure amongst the global population is boosting the growth of the biosimilars market. The biosimilars provide treatment to various chronic diseases at affordable costs and hence it is gaining popularity among the global consumers.The rising prevalence of diabetes is another major driver that may boost the demand for the biosimilar drugs. According to the World Health Organization, diabetes is the major reason behind the blindness, kidney failure, stroke, and heart attacks. The availability of affordable biosimilar drugs for the treatment of such serious diseases is boosting the market growth.

The complexities related to the manufacturing of the biosimilar drugs and huge capital investments are the major drawbacks that can restrict market growth. Moreover, lack of awareness regarding the availability of biosimilars among the population especially in the developing and underdeveloped regions are the potential factors that may hamper the market growth during the forecast period.

Based on the product, the monoclonal antibodies segment was the dominant segment in 2020. The extensive usage of monoclonal antibodies in the treatment of variousdiseases such as cancer, rheumatoid arthritis, cardiovascular diseases, and multiple sclerosis. This segment accounts for over 25% of the market share. The higher effectiveness of the monoclonal antibodies in the treatment of the cancer and diabetes is expected to drive the segment growth further in the upcoming years.

Based on the application, the oncology segment dominated the market in 2020. According to the International Agency for Research on Cancer, around 19.3 million new cancer cases and around 10 million cancer related deaths were reported in the year 2020, across the globe. Prevalence of breast cancer in the female population is surging, accounting for around 11.7% of the new cancer cases followed by the lungs cancer that accounted for 11.4% and colorectal cancer accounted for 10.0% in 2020. Hence, the growing demand for the biosimilar drugs for the treatment of cancer is boosting the segment growth.

In 2020, Pfizer obtained the FDA approval for its Nyvepria, which is used for lowering the infection incidences.In May 2020, Fresenius Kabi acquired approval for its MSB11455, a pegfilgrastim biosimilar, from both the FDA and EMA. Drug approval is a major strategy adopted by the market players. The various other developmental strategies like acquisition, partnerships, mergers, and government policies fosters market growth and offers lucrative growth opportunities to the market players.

Competitive Intelligence

The report provides an understanding of the market composition and explains the role of established players and regional contributors. It is essential for the market players to make calculative moves and focus on client acquisition and retention. The detailed company profiles will provide the necessary intelligence to the reader. In order to maintain their share, the market players are focusing on strategies such as cross-border expansion, product differentiation and so on.

Some of the prominent players in the global biosimilars market are listed as below:

  • Novartis
  • Synthon Pharmaceuticals, Inc.
  • TevaPharmaceutical Industries Ltd.
  • LG Life Sciences
  • Celltrion
  • Biocon
  • Hospira
  • Merck Serono
  • Biogen idec, Inc.
  • Genentech

Segments Covered in the Report

By Product

  • Monoclonal Antibodies
  • Glucagon
  • Insulin
  • Erythropoietin
  • Interferon
  • Calcitonin
  • Others

By Application

  • Oncology
  • Growth Hormonal Deficiency
  • Blood Disorders
  • Chronic & Autoimmune Disorders
  • Others

Regional Segmentation

– North America (U.S. and Canada)

 – Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)

 – Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)

 – Latin America (Brazil and Rest of Latin America)

– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Biosimilars Market 

5.1. COVID-19 Landscape: Biosimilars Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Biosimilars Market, By Product

8.1. Biosimilars Market, by Product Type, 2021-2030

8.1.1. Monoclonal Antibodies

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Glucagon

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Insulin

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Erythropoietin

8.1.4.1. Market Revenue and Forecast (2019-2030)

8.1.5. Interferon

8.1.5.1. Market Revenue and Forecast (2019-2030)

8.1.6. Calcitonin

8.1.6.1. Market Revenue and Forecast (2019-2030)

8.1.7. Others

8.1.7.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Biosimilars Market, By Application

9.1. Biosimilars Market, by Application, 2021-2030

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Growth Hormonal Deficiency

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Blood Disorders

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Chronic & Autoimmune Disorders

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Biosimilars Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Product (2019-2030)

10.1.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Product (2019-2030)

10.1.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Product (2019-2030)

10.5.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

Chapter 11. Company Profiles

11.1. Novartis

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Synthon Pharmaceuticals, Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. TevaPharmaceutical Industries Ltd.

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. LG Life Sciences

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Celltrion

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Biocon

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Hospira

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Merck Serono

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Biogen idec, Inc.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Genentech

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Why should you invest in this report?

If you are aiming to enter the global biosimilars market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for biosimilars are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable. 

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1359

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Show More

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Related Articles

Back to top button